about
Towards a personalised approach to managing influenza infections in infants and children - food for thought and a note on oseltamivir.Antiviral resistance and correlates of virologic failure in the first cohort of HIV-infected children gaining access to structured antiretroviral therapy in Lima, Peru: a cross-sectional analysisQuantitative influenza follow-up testing (QIFT)--a novel biomarker for the monitoring of disease activity at the point-of-care.Adverse respiratory symptoms and environmental exposures among children and adolescents following Hurricane Katrina.Enabling Precision Medicine With Digital Case Classification at the Point-of-Care.All that palsies is not Bell's -the need to define Bell's palsy as an adverse event following immunization.Educating parents about the vaccination status of their children: A user-centered mobile applicationIntroducing new vaccines in developing countries.Standardization and simplification of vaccination records.Influenza and other respiratory viruses: standardizing disease severity in surveillance and clinical trials.Prospective surveillance of antiviral resistance in hospitalized infants less than 12 months of age with A(H3N2) influenza infection and treated with oseltamivir.The importance of the patient voice in vaccination and vaccine safety-are we listening?Communicating vaccine safety to the media and general public.Innovative Digital Tools and Surveillance Systems for the Timely Detection of Adverse Events at the Point of Care: A Proof-of-Concept Study.Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy.Vaccine safety monitoring systems in developing countries: an example of the Vietnam model.A design thinking approach to effective vaccine safety communication.Evaluation of novel second-generation RSV and influenza rapid tests at the point of care.A prospective observational study of oseltamivir safety and tolerability in infants and young children ≤24 months.The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach.Controlled language and information on vaccines: application to package inserts.Prioritizing polio.Vienna Vaccine Safety Initiative.Teaching vaccine safety communication to medical students and health professionals.Awareness and utilization of reporting pathways for adverse events following immunization: online survey among pediatricians in Russia and Germany.Early detection of influenza A and B infection in infants and children using conventional and fluorescence-based rapid testing.Evaluating the Brighton Collaboration case definitions, aseptic meningitis, encephalitis, myelitis, and acute disseminated encephalomyelitis, by systematic analysis of 255 clinical cases.A comparative analysis of psychological trauma experienced by children and young adults in two scenarios: evacuation after a natural disaster vs forced migration to escape armed conflict.Editorial: Communicating vaccine safety - the Vienna Vaccine Safety Initiative.Can we distinguish respiratory viral infections based on clinical features? A prospective pediatric cohort compared to systematic literature reviewAre we missing respiratory viral infections in infants and children? Comparison of a hospital-based quality management system with standard of careIncidence, Severity and Impact of Influenza: a joint meeting organised by the ISIRV Epidemiology Group and ECDC, Stockholm, 2019.The impact of the parent-physician relationship on parental vaccine safety perceptionsGlobal patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysisPartnering for enhanced digital surveillance of influenza-like disease and the effect of antivirals and vaccines (PEDSIDEA)Using a mobile application to detect health needs among children and adolescents who are newly arrived migrants in EuropeNeuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection
P50
Q30430563-0938DFA5-D8DF-44D1-9AAF-6DF88823CC4DQ34528801-54F2B568-DA01-43AB-93E1-37FAE2C1FA71Q35128031-FD84BD80-AF89-4CEC-B973-165B57E4E572Q35258229-8B52A10C-D335-417B-AD3F-400AF5626795Q36645032-957ED701-48DA-418F-AD03-D8B7ABD1E117Q37013981-25EB7EE1-A72B-456C-A22C-E29E4AA4D648Q37600715-82B24AD2-138E-44E8-8378-8179D3371B3EQ38160253-967381AC-2056-44DE-80AC-E0E4A953DF88Q38193522-976A3850-9414-4364-9FAE-3C9415503CE9Q38917864-C4F10AB7-3A0B-4DEA-AD49-157407A3E33BQ38958222-97F24425-B8E0-4922-92C7-35274AD83F2BQ39113525-3DF19C12-E429-408A-9F2C-62287FA14D4DQ39330469-E81DCC5F-0982-4D61-9A3B-FE28D050D6D8Q39650695-87917188-7414-4568-ACFD-7FA61DC42281Q40748977-6CB5243A-B7D9-469F-A569-D501F96359E4Q41093515-D2343B86-B145-4476-8CAC-46ED29F58981Q41347121-D02D8415-F7CB-459A-BA8B-4D7F247CE38FQ41547918-4F6B44BB-63F5-4F6C-9836-BD5CD3794FDCQ41694420-9EA0DCA8-42BC-488E-B029-8FDB6DFB6CAFQ42216493-4ABB1B09-7326-46C3-A204-F02FFD7ED6D2Q43331797-A088266A-0824-46AD-9462-72CC0B97E953Q46892437-F81B95A8-D186-4B12-A634-E9EBC0702A84Q50071052-7E50E5F4-39FB-4D00-8E87-7C51D555E40EQ50568714-EEBC8BD2-49E1-4E33-A235-2F1FF07B8E4EQ50682460-4E92639F-C3B3-4618-BE9A-EAD3ED9292C1Q50917130-8418404F-66CA-475C-AEEA-31EB2F2511A7Q51717086-E4CFA491-7807-4FE3-BB7B-B4A20AFC142EQ52690867-B995EF28-92B7-4916-B7B1-C766C7151834Q52867861-93974200-1227-4E8D-B035-AF982F50A20AQ56961534-1033A4A4-3F44-4927-9071-B69E723C0959Q56966416-4B35E374-F3AD-41A3-9D0B-96CF54732BE1Q64969590-969CC6F1-0E2E-4871-A395-816621EE24AAQ87089177-79C03ACB-A213-41B8-B415-D081B0A06A03Q91861500-705ECBDB-AB86-47D6-A000-7BC4684818E5Q92557510-BE827D40-C6F9-411B-958A-0A9CE439E3A2Q93035917-DB970C7A-DF3C-4D2F-86CD-0816DB360900Q95729248-30DD5DC3-C21E-4C3C-8E99-2C19A00C5E46
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Barbara Rath
@en
Barbara Rath
@nl
type
label
Barbara Rath
@en
Barbara Rath
@nl
prefLabel
Barbara Rath
@en
Barbara Rath
@nl
P31
P496
0000-0001-5181-8417